Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323242 | 0.83 | KMT2A (0.47) | KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL5969982 | 0.82 | FABP5 (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL14559049 | 0.82 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL28730478 | 0.82 | KMT2A (0.62) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL119279 | 0.81 | FABP5 (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL16612468 | 0.79 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL14656652 | 0.79 | KMT2A (0.47) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL14300816 | 0.78 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL26123657 | 0.78 | KMT2A (0.42) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL20371103 | 0.78 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20220194916-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-20210047284-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20200247774-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200024248-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2020-01-23 | — | — | US | disclosed |
| US-20190233387-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| EP-2963031-B1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS INC (US) | 2019-02-06 | — | — | EP | disclosed |
| US-20190031637-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180208572-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS INC (US) | 2018-07-26 | — | — | US | disclosed |
| US-20170088533-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ALLTRANZ INC. | 2017-03-30 | — | — | US | disclosed |
| EP-2963031-A2 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | Zynerba Pharmaceuticals, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150218121-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2015-08-06 | — | — | US | disclosed |
| EP-2215071-B1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS INC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-8980942-B2 | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | ZYNERBA PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120289484-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ALLTRANZ INC. | 2012-11-15 | — | — | US | disclosed |
| US-8227627-B2 | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | ALLTRANZ INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2215071-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | AllTranz Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009073633-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143462-A1 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same | ALLTRANZ (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208572-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885FABP5 2054/4885FABP7 808/4885 |
| US-20120289484-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885FABP5 2054/4885FABP7 808/4885 |
| US-20200247774-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885FABP5 2054/4885FABP7 808/4885 |
| US-20190233387-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885FABP5 2054/4885FABP7 808/4885 |
| US-20200024248-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885FABP5 2054/4885FABP7 808/4885 |
| US-20150218121-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885FABP5 2054/4885FABP7 808/4885 |
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1832/4885FABP5 2269/4885FABP7 844/4885 |
| US-20090143462-A1 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same | CNR2, CNR1, FAAH | KMT2A 1787/4885FABP5 2058/4885FABP7 737/4885 |
| US-20220194916-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885FABP5 2054/4885FABP7 808/4885 |
| US-20190031637-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885FABP5 2054/4885FABP7 808/4885 |
| US-20170088533-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885FABP5 2054/4885FABP7 808/4885 |
| US-20210047284-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885FABP5 2054/4885FABP7 808/4885 |
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1832/4885FABP5 2269/4885FABP7 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.